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Abbreviations
Aβ  - Amyloid β protein
AD  - Alzheimer’s disease
AICD - APP intracellular domain
APP  - Amyloid precursor protein
BACE1  - β-secretase
BDNF  - Brain-derived neurotrophic factor
Cer  - Ceramides
Cdk5  - Cyclin-dependent kinase 5
GSK-3β  - Glycogen synthase kinase-3β
NFT  - Geurofibrillary tangles
PA  - Palmitic acid
PHF  - Paired helical filaments
PI3-K  - Phosphatidylinositide 3-kinase
PP2A  - Protein phosphatase 2A
NFT  - Neurofibrillary tangles
SM  - Sphingomyelinase
SPT  - Serine palmitoyltransferase
A link between 
hyperphosphorylated tau, Aβ, 
and lipids
Alzheimer’s disease (AD) is a chronic 
progressive neurodegenerative disorder and 
the leading cause of dementia syndrome in 
elderly people. Existing treatments for AD 
do not delay or modify progression of the 
disease, and the number of affected people is 
estimated to rise to 100 million worldwide by 
2050 without new effective therapy [1]. Besides 
age that is considered the most significant 
risk factor for AD, epidemiological studies 
indicate that a high-fat diet might contribute 
to its development, the degree of saturation 
of fatty acid being the most important factor 
determining risk [2,3]. In fact, white matter 
from AD brain is characterized by increased 
fatty acid content, although the cholesterol 
levels are decreased in comparison to healthy 
subjects [4,5]. Hence, understanding the 
etiopathological processes of AD, particularly 
in respect of lipid contributions, is of major 
importance for the development of novel 
therapeutic strategies that will reverse or slow 
down progression of the disease.
The most researched neuropathological 
hallmarks found in AD brains are extracellular 
senile plaques containing neurotoxic amyloid 
β-peptide (Aβ) derived from the amyloid 
precursor protein (APP), and intracellular 
aggregates of abnormally phosphorylated tau 
protein that form paired helical filaments (PHF). 
They associate and build up densely packed 
networks of neurofibrillary tangles (NFT) [6-8]. 
Besides AD, phosphorylation of tau protein is 
also implicated in the pathogenesis of several 
related disorders called tauopathies [9,10]. 
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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the extracellular deposits 
of β amyloid peptides (Aβ) in senile plaques, and intracellular aggregates of hyperphosphorylated tau in 
neurofibrillary tangles (NFT). Although accumulation of Aβ has been long considered a leading hypothesis in 
the disease pathology, it is increasingly evident that the role hyperphosphorylation of tau in destabilization 
of microtubule assembly and disturbance of axonal transport is equally detrimental in the neurodegenerative 
process. The main kinase involved in phosphorylation of tau is glycogen-synthase kinase 3-beta (GSK-3β). 
Intracellular accumulation of Aβ also likely induces increase in hyperphosphorylated tau by a mechanism 
dependent on GSK-3β. In addition, Aβ affects production of ceramides, the major sphingolipids in mammalian 
cells, by acting on sphingomyelinases, enzymes responsible for the catabolic formation of ceramides from the 
sphingomyelin. Generated ceramides in turn increase production of Aβ by acting on β-secretase, a key enzyme 
in the proteolytic processing of the amyloid precursor protein (APP), altogether leading to a ceramide-Aβ-
hyperphosphorylated tau cascade that ends in neuronal death. Modulators and inhibitors acting on members of 
this devastating cascade are considered as potential targets for AD therapy. There is still no adequate treatment 
for AD patients. Novel therapeutic strategies increasingly consider the combination of multiple targets and 
interactions among the key members of implicated molecular pathways. This review summarizes recent findings 
and therapeutic perspectives in the pathology and treatment of AD, with the emphasis on the interplay between 
hyperphosphorylated tau, amyloid β, and sphingolipid mediators.
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Although formation of insoluble Aβ 
fragments in an amyloidogenic pathway 
by proteolytic cleavage of APP with β- and 
γ-secretases has been considered a key step 
in the pathogenesis of AD, tau increasingly 
emerged as an obligatory member of the 
neurodegenerative process [1]. Moreover, 
a number of reports found evidence for a 
relationship between Aβ and tau in AD [11-14]. 
Soluble Aβ oligomers facilitate wild-type human 
tau accumulation and hyperphosphorylation, 
leading to neuritic dystrophy [15], and learning 
and memory deficits in transgenic mice [16]. 
In addition, treatments with modulators of 
γ-secretase can reverse Aβ-associated tau 
pathology and reduce hyperphosphorylated 
tau levels in AD mouse models [17,18]. 
Interactions between tau and lipids also seem 
important in AD pathology. Phosphorylated 
tau was found in specific microdomains of 
plasma membrane called lipid rafts in neuronal 
cells exposed to Aβ peptides [19], in lipid rafts 
of an AD mouse model, and in lipid rafts from 
AD brain [20]. Evidence indicates connections 
between lipids and Aβ as well. While 
proteolytic processing of APP is influenced by 
the lipid composition of cellular membranes, 
particularly with cholesterol and sphingolipids, 
Aβ in turn plays an essential role in regulating 
lipid homeostasis [21].
Tau protein and axonal assembly 
and stability 
Tau, a protein with multiple phosphorylation 
sites, belongs to the family of microtubule-
associated proteins. It is highly expressed in 
neurons, particularly in axons, with an essential 
role in the assembly of tubulin monomers into 
microtubules that are fundamental cellular 
structures for preservation of neuronal shape 
and axonal transport [22]. Therefore, tau plays 
a crucial role in the formation and maintenance 
of axons, microtubule dynamics, neurite 
outgrowth, and neuritic stability [23]. 
Tau is encoded by a single gene, but due 
to alternative splicing of mRNA, several 
tau isoforms with differential affinity for 
microtubules are expressed in human brain 
in a developmental [24], cell-specific, and 
pathology-related manner [25,26]. In early 
developmental stages only the smallest tau 
isoform is expressed, while all tau isoforms 
are expressed during adulthood [27]. These 
isoforms differ by the presence of either three 
or four semiconserved repeat-regions in the 
C-terminus part of the molecule that form 
highly homologous microtubule-binding 
domain, and by the presence of two, one, or no 
inserts in the N-terminus part. Through these 
microtubule-binding repeats at the C-terminus, 
tau protein exerts its specific function in 
microtubule assembly and stabilization [28,29]. 
At the level of both mRNA and protein, a ratio 
of tau isoforms with 4 and 3 repeats (4R:3R) is 
approximately equal in healthy adult brain [30]. 
Alterations in 4R:3R ratio and mutations in the 
tau gene that cause amino acid substitutions 
lead to formation of intracellular inclusions 
consisting of highly phosphorylated tau with 
abnormal conformation [1,31].
Hyperphosphorylation of tau leads to 
toxicity and loss of function
Function of tau is modulated by alterations 
in its phosphorylation pattern, in principle 
on various threonine (Thr) and serine (Ser) 
residues. The longest human isoform has 
80 Ser and Thr residues and additional 5 
tyrosine residues indicating that almost 20% 
of the molecule are amino acids that can be 
phosphorylated [32]. The exact contribution 
of each phosphorylation sites or subsets of 
phosphorylation sites for normal tau function is 
still not completely understood. The normal tau 
contains 2-3 moles of phosphate per mole of 
protein, while in AD brain this phosphorylation 
stoichiometry is three to four times higher, 
with all isoforms being found in abnormally 
phosphorylated NFT [33]. By mass spectroscopy 
and antibody staining, the total number of 
identified phosphorylated residues in insoluble 
tau from AD brains is 45, which is significantly 
higher than the number of phosphorylated 
residues in soluble tau of healthy controls, and 
represents more than half of residues available 
for phosphorylation [1,34,35].
Hyperphosphorylation results in dissociation 
of tau protein from microtubules and 
impairs its role in microtubule assembly and 
stabilization, leading to the loss of the normal 
content of microtubules [36]. Certain residues, 
either within the microtubule-binding domain 
or apart from it, such as Thr212, Ser214, Thr231, 
Ser235 and Ser262, have been recognized as the 
major sites contributing to the segregation of 
tau protein from the microtubules [37-39]. In 
addition, hyperphosphorylation deregulates 
axonal transport of vesicles and other cargoes 
further affecting axonal length and function. 
This ends in neuronal degeneration, synaptic 
loss, and ultimately cell death, a key end-point 
histopathological hallmark of AD [9,30,32,40]. 
In addition to phosphorylation-dependent 
loss of function, aberrant phosphorylation 
of tau induces tau-tau interactions and 
self-assembly into tangles of paired helical 
filaments that build up NFT inside neurons 
[41]. Development of NFT occurs in a stepwise 
manner, and the specific pattern of tau 
phosphorylation correlates with severity of 
neuronal cytopathology [42]. The appearance 
of pathological changes can be classified in 
three morphological stages: pre-neurofibrillary 
tangle, intra-, and extra neuronal fibrillary 
tangles [43]. NFT also appear in a stereotypical 
order, certain regions being affected before 
others [44-48]. 
Tau can be phosphorylated by proline-
directed and non-proline directed kinases 
[49,50]. In vitro and cell studies revealed 
that tau is a substrate for at least 17 different 
kinases with considerable overlap of the 
phosphorylated residues [1,51]. Among them 
are glycogen synthase kinase-3β (GSK-3β), 
cyclin-dependent kinase 5 (cdk5) and its 
regulators, non-receptor tyrosine kinases, 
casein kinase 1 delta, extracellular signal 
regulated kinase-2 (ERK2), and cyclic AMP-
dependent protein kinase [52-57]. Despite 
much advances in identifying phosphorylation 
sites in vitro, the individual contributions of 
each kinase to in vivo physiology and pathology 
are still unknown. The considerable overlap of 
multiple residues phosphorylated by different 
kinases in vitro suggests that the overall 
pattern of increased tau phosphorylation 
is more important than phosphorylation 
of each particular residue. On the contrary, 
diverse phosphatases remove phosphate 
groups and dephosphorylated tau. Protein 
phosphatase 2A (PP2A) seems to be the major 
tau phosphatase in human brain [58]. Hence, 
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coordinated action of protein kinases and 
phosphatases determines the phosphorylation 
status of tau, suggesting that downregulation 
of phosphatases in the AD brain could also 
lead to tau hyperphosporylation and the 
prevalence of abnormal, stable tau form with 
high aggregation potential [59,60].
GSK-3β as a link between 
hyperphosphorylated tau and Aβ
GSK-3 is a ubiquitous Ser/Thr kinase that 
modulates many important processes inside 
the cell. It has two highly homologous isoforms 
- GSK-3α and GSK-3β. Activation of GSK-3 has 
been found in a number of neurodegenerative 
diseases, including AD. Active GSK-3 localizes 
to pretangle neurons, dystrophic neurites and 
NFT in AD brains, and temporal and spatial 
patterns of GSK-3 expression correlate well 
with the progression of neurodegeneration 
[61-63]. Altered activity of both GSK-3 isozymes 
contributes to key neuropathological hallmarks 
of AD. While GSK-3α participates in APP 
processing and deposition of Aβ by regulating 
the activity of γ-secretase [64], the other 
isoform GSK-3β is considered as the major tau 
kinase involved in hyperphosphorylation of tau 
protein [65,66]. As previously explained, GSK-
3β-mediated phosphorylation of tau reduces 
its affinity for microtubules, and also modulates 
axonal transport [65,67]. 
GSK-3β recognizes phosphorylated 
Ser residues, and phosphorylates Ser and 
Thr residues in the vicinity of previously 
phosphorylated Ser residues. It requires prior-
phosphorylation by cdk5 in vitro [68], while 
evidence for in vivo priming is still missing. 
Studies on transgenic mice also suggested 
a crucial role of GSK-3β in AD pathogenesis 
[69], and a role of cdk5 in elevation of tau 
hyperphosphorylation and NFT formation [70]. 
Phosphorylation of tau by GSK-3β may promote 
formation of tangle-like filament morphology in 
cell-free models [71]. GSK-3β also mediates tau 
phosphorylation in cultured cell lines [72], while 
overactivation of GSK-3 in animal model induces 
tau hyperphosphorylation together with AD-like 
cognitive effects such as impairment of spatial 
memory [73]. Most importantly, it was shown 
that Aβ oligomers enhance tau phosphorylation 
(Figure 1) and compromise cell survival through 
the mechanism mediated by GSK-3β activation 
[12,14,69], and neurons from tau-knockout 
mice are resistant to Aβ-induced toxicity [11]. 
Moreover, it has been reported that GSK-3β 
facilitate APP processing and generation of 
Aβ [74]. Interestingly, presenilin 1, a part of 
γ-secretase, brings tau and GSK-3β in close 
proximity as both tau and GSK-3β bind to the 
same region of presenilin 1 [75]. Altogether 
these observations suggest that GSK-3β plays 
a central role in the pathological progression 
of neurodegeneration in vivo, and points to 
its great potential as a target for therapeutic 
interventions in AD.
Inhibition of tau phosphorylation 
and pharmacological outcomes
GSK-3β is considered an interesting therapeutic 
target, because it links senescence, metabolic 
diseases, inflammation, protein aggregation, 
and cell death [76,77]. Accordingly, inhibitors 
of GSK-3β activity have been intensively sought 
as potential pharmacological agents in AD 
therapy. Many studies were performed using 
lithium, the most widely used mood stabilizer 
for treating bipolar disorder.  However, lithium 
is a specific inhibitor of neither GSK-3, nor GSK-
3β. It acts as a competitive inhibitor of Mg2+ and 
increases inhibitory phosphorylation at Ser9 in 
GSK-3β through the activation of Akt kinase 
[78]. Briefly, studies on transgenic mice have 
shown that inhibition of GSK-3β effectively 
reduces tau pathology, including level of 
tau phosphorylation, formation of insoluble 
aggregates, and axonal degeneration, 
particularly if administration started during 
early stages of NFT development (Table 1). 
However, despite the overall reduction in 
phosphorylated tau, treatment with lithium 
failed to improve memory impairments in 
some studies [79-81]. 
Regarding Aβ pathology, treatments with 
lithium resulted in contradictory outcomes. 
While some studies showed reduced Aβ level 
and reduced plaques formation [74], increased 
Aβ production [64], as well as unchanged 
Aβ production have been reported [77,80]. 
A more recent study on a double transgenic 
Figure 1.  Schematic representation of the interactions between hyperphosphorylated tau, Aβ, and ceramides.
GSK-3β is the main kinase involved in phosphorylation of tau. By a mechanism that is dependent on 
GSK-3β, intracellular accumulation of Aβ may also contribute to tau hyperphosphorylation. In addition, 
Aβ affects production of ceramides by acting on sphingomyelinases, enzymes responsible for the 
catabolic degradation of sphingomyelin. Generated ceramides in turn increase production of Aβ acting 
on β-secretase, a key enzyme in the proteolytic processing of amyloid precursor protein (APP). BDNF 
and presenilin may modulate these interactions, particularly via the PI3-K/Akt signaling pathway. PI3-K 
activates Akt/protein kinase B, while activated Akt in turn phosphorylates GSK-3β and induces its 
inactivation and reduction in tau phosphorylation.
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Table 1.  Effects of GSK-3 inhibitors on tau and Aβ pathology in diverse transgenic mice models.
Mouse line Age of mice GSK-3 inhibitor Dose Treatment duration Eects on AD pathology Ref
Tauvlw adult LiCl Fed with chow
1.7 g/kg + 2.55 g/kg
4 weeks + 2 weeks
↓ of tau protein in sarkosyl-insoluble fractions
↓phosphorylation and aggregation of mutant 
tau
[129]
PDAPP 4 weeks Li2CO3 2.4 g/kg chow 7 months
↓ Aβ levels
↓ Aβ plaque deposition
[74]




↓ level of aggregated tau in the cortex
↓ axonal degeneration if treatment was started 
at an early stage
[78]
JNPL3 8-11 months AR-A014418 30 mmol/kg
Twice daily for 1 
month
↓ insoluble tau levels in the brain stem [78]




↓ tau lesions (promotion of ubiquitination)
development of more soluble tau aggregates in 
spinal cord
no obvious effect on tau phosphorylation
↓ number of tau-positive spheroids in spinal cord 
at 9 months
[130]
PrP T44 Ag 5-9 months LiCl
2.0 g per
kg chow
5 months limited clearance of tau aggregates [130]
GSK-3/VLW 12 months LiCl 1.7 g LiCl/kg chow 7.5 months
no signs of phospho-tau accumulation or ag-
gregation
[131]
GSK-3/VLW 18 months LiCl
Fed with chow
1.7 g/kg + 2.55 g/kg
4 weeks + 2 weeks
incomplete reversal of tau pathology
without effect on amyloid-like pathology
[131]
hAPP tg 3 months LiCl 20 mg/kg 3 months
Improved water maze performance
↓ Aβ and plaques formation
↓ Aβ phosphorylation of APP
[132]
3xTg-AD 15 months LiCl 300 µl of 0.6 mol/l 4 weeks
↓ tau phosphorylation
unchanged Aβ load
without improvement in working memory 
deficits 
[80]
APPsw-tauvlw 9 or 12 months NP12 200 mg/kg 3 months
↓levels of tau phosphorylation
↓Aβ deposition
↓ astrocytic proliferation
preserved neuronal survival in the entorhinal 
cortex and CA1
prevention of memory deficits
[81]
Tgtau30 3 months Li2CO3
Chronic chow feeding
2.4 g/kg chow
8 months no changes in the development of NFT [133]




↓ tau phosphorylation and sarkosyl-insoluble 
aggregated tau in CNS
↓density of NFT
without effect on tau ubiquitination
↑ LC3, marker of autophagic vacuoles
motor and working memory deficits not rescued
[133]
3xTg-AD 13 months MMBO 3 and 10 mg/kg 22 days
↓tau phosphorylation
improved cognitive behavioral deficit
without changes in Aβ level and Aβ plaque 
formation
[134]
3xTg-AD 13 months C-7a 20 and 50 mg/kg Twice daily for 21 days
↓tau phosphorylation in hippocampus 
prevention of short-term memory deficitc
[135]
Tauvlw- transgenic for a human 4-repeat tau isoform with 2 N-terminal exons carrying the FTDP-17 mutations G272V, P301L and R406W; PDAPP - overexpressing the human 
amyloid precursor protein containing the Indiana familial AD mutation (APPV717F); JNPL3 - line overexpressing mutant human tau (P301L, 4R0N);  PrP T44 Tg – overexpression 
of the smallest human tau isoform in the mouse CNS with the mouse prion protein (PrP) promoter; GSK-3/VLW - mice overexpressing GSK-3 and FTDP-17-tau;  hAPPtg – tg 
mice expressing mutant human APP under the Thy1 promoter; 3xTg-AD mice – line expressing human APPSwe and the human tauP301L; APP
sw-tauvlw- overexpressing human 
mutant APP (Swedish mutation K670N-M671L) and a triple human tau mutation associated with frontotemporal dementia and parkinsonism linked to chromosome 17 
(G272V, P301L and R406W); Tgtau30 express a mutant tau transgene (1N4R human tau isoform) mutated at positions G272V and P301S, under the control of a modified 
thy-1 promoter; MMBO -2 -methyl-5-(3{4[(S)methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole
APP/Tau mouse model with a specific GSK-3 
inhibitor reduced tau phosphorylation and 
Aβ deposition, together with prevention of 
memory deficits and increase in neuronal 
survival [81]. Other selective inhibitors of 
GSK-3α/β also suggested reduction in Aβ 
production, in particular via an increase of the 
degradation of APP through the activation of 
a lysosome/autophagy pathway [77]. Based 
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on these promising findings, some GSK-3 
inhibitors have entered into preclinical and 
clinical trials [82,83]. 
Numerous factors may affect tau 
phosphorylation, and many of them are also 
assessed for pharmacological application in 
AD patients. Brain-derived neurotrophic factor 
(BDNF), an extracellular factor that is down-
regulated in AD brains, has been considered as 
one of the critical contributors to dementia due 
to its role in cognition, learning, and memory 
through the modulation of synaptic plasticity 
in adulthood [84,85]. Regarding GSK-3β, 
exposure to BDNF induces a rapid decrease in 
tau phosphorylation at specific phosphorylation 
sites through a PI3-K/Akt and downstream GSK-
3β signaling transduction cascade [86]. PI3-K 
activates Akt/protein kinase B, while activated 
Akt in turn phosphorylates GSK-3β and induces 
its inactivation (Figure 1). Moreover, Aβ at levels 
insufficient to cause degeneration interferes with 
BDNF-induced activation of PI3-K/Akt pathway 
[87], indicating a potential link between an 
increase in Aβ levels and hyperphosphorylation 
of tau protein in AD, which may be of 
importance for novel therapeutic approaches 
[86]. In contrast, accumulation of Aβ leads to 
downregulation of Akt, increase in activation of 
GSK-3β, and apoptosis, while downregulation 
of Akt paralleled intracellular Aβ accumulation 
in  vivo in the Tg2576 AD mouse model [88]. 
Interestingly, presenilin 1 also induces tau 
dephosphorylation and promote cell survival 
due to PI-3K/Akt-mediated inhibition of GSK-3 
activity [89].
Sphingolipids in the 
pathogenesis of AD
Sphingolipids are a heterogeneous class of 
lipids derived from sphingosine, an aliphatic 
amino alcohol. The first, rate-limiting step in 
their synthesis is formation of sphingosine 
from palmitoyl-CoA and Ser by serine 
palmitoyltransferase (SPT). Beside important 
structural role, particularly in lipid rafts, 
sphingolipids and their metabolites also act 
as second messengers in diverse signaling 
pathways involved in signal transduction, cell 
growth and differentiation, and apoptosis 
[90,91]. Although sphingolipids represent only 
a small proportion of the total cellular lipid 
pool [92], studies suggest that even subtle 
disturbances in their balance may be involved 
in the development of neurodegenerative 
diseases. Diverse methodological approaches 
have identified altered pathways and 
products of sphingolipid metabolism that 
contribute to the pathogenesis of AD, 
including Aβ pathology, tau formation, 
and neurodegeneration [93-95]. Hence, 
preservation of neuronal sphingolipid 
homeostasis is of major importance for 
normal brain functioning and potential target 
for novel therapeutic approaches.
The major bioactive mediators formed 
by sphingolipid metabolism are multiple 
ceramides, sphingosine, ceramide-1-
phosphate, sphingosine-1-phosphate and 
glycosphingolipids [92,95]. Several studies 
indicated that ceramides and sphingosine 
mediate apoptosis, growth arrest, and 
senescence, while their phosphorylated 
derivatives promote proliferative and anti-
apoptotic activities [92,96], although it is also 
observed that endogenous and exogenous 
ceramides could protect cortical neurons 
obtained from wild-type mice against Aβ toxicity 
and Aβ-induced increase in tau phosphorylation 
by inhibiting cdk5 activity [97]. Irrespective 
of this controversial finding, it is evident that 
neuronal survival could be determined with very 
small shifts in ceramide metabolism [98].  
Sphingolipids in AD 
Ceramides (Cer), the major molecules of 
sphingolipid metabolic pathways, are 
expressed in both neurons and astrocytes. 
They are composed of sphingosine attached 
by an amide bond to fatty acids, varying in 
length from 14 to 26 carbon atoms. On this 
basic backbone, different moieties can be 
attached forming complex sphingolipids 
[91,99]. Hence, glycosphingolipids are formed 
through Cer glycosylation. Shift in sphingolipid 
metabolism toward accumulation of Cer and 
decrease of glycosphingolipids, together with 
the reduction of anti-apoptotic signaling, has 
been suggested as a function of the disease 
progression [100]. On human neuroblastoma 
SH-SY5Y cells, inhibition of glycosphingolipids 
biosynthesis markedly reduced secretion 
of soluble APP and Aβ, indicating one more 
potential therapeutic avenue in the inhibition 
of Aβ production [101]. 
Sphingomyelin, one of the most abundant 
mammalian sphingolipid especially 
enriched in the myelin sheet that surrounds 
axons of neuronal cells, is formed when 
phosphorylcholine is attached to Cer. Increased 
levels of sphingomyelin are found in the 
cerebrospinal fluids of patients in prodromal AD 
exclusively [102], and increased sphingomyelin/
Cer ratio is considered for potential use as 
sensitive blood-based biomarker for disease 
progression [103].
Sphingosine, formed in the deacylation of 
Cer by enzyme ceramidase, can be metabolized 
to sphingosine-1-phosphate and fine-tuning 
between concentrations of these metabolites 
may determine cell fate [95]. As mentioned 
above, effects of sphingosine-1-phosphate 
are considered mostly as beneficial [96], 
although the proteolytic activity of β-secretase 
may be increased in direct interaction with 
sphingosine-1-phosphate [104]. 
Gangliosides, a highly heterogeneous family 
of glycosphingolipids that contain sialic acid, 
are also concentrated in lipid rafts, and able 
to affect neuronal plasticity and cell survival. 
Composition and amount of some gangliosides 
change with age, and it is thought that 
gangliosides also contribute to AD pathology 
by binding to Aβ that further leads to the 
formation of large Aβ assemblies [105-107]. 
Sulfatides, sulfated galactocerebrosides 
synthesized almost exclusively by 
oligodendrocytes and present predominantly 
in the myelin sheath, are also a class of 
sphingolipids probably involved in AD 
pathogenesis [107]. It seems that levels 
of sulfatides are depleted in AD brains, 
particularly at the stage of very mild dementia 
[108].  Interestingly, it has been shown that 
sulfatides may function as effective stimulators 
for autophosphorylation of GSK-3β [109].
Anabolic and catabolic pathways 
of sphingolipid metabolism: 
implications for AD pathology
Sphingomyelin can be hydrolyzed to Cer 
through the actions of ubiquitous acidic and 
brain-specific neutral sphingomyelinases 
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that are activated by oxidative stress and 
inflammatory processes [98]. In SH-SY5Y 
cells and primary cortical neurons, the 
proinflammatory modulator TNF-α stimulates 
Mg2+-dependent neutral sphingomyelinase 
activity, and elicits sphingomyelin hydrolysis 
and Cer increase [98]. Endogenous Cer can also 
be generated by a de novo synthesis pathway. 
Elevated basal level of particular species of 
Cer in serum is associated with a higher risk 
for developing AD [110]. Cer are increased 
approximately three times in brains from AD 
patients [108], particularly in vulnerable regions 
[111]. Besides increased levels of Cer [112], 
gene expression abnormalities of enzymes 
that participate in sphingolipid metabolism, 
including both sphingomyelinases, are also 
found at different stages of AD progression 
[113]. A detailed RNA analysis revealed 28 
genes involved in Cer homeostasis whose 
expression was altered through the disease 
progression. In particular, gene expression of 
the enzymes involved in de novo synthesis of 
Cer was increased, while downregulation of 
the enzymes participating in glycospingolipid 
synthesis occurred [100].
Because Cer exhibit neurotoxic properties 
acting as pro-apototic molecules, increased 
activity of sphingomyelinases promotes loss of 
neuronal cells [112,114,115]. The mechanism 
leading to cell death may involve, at least in part, 
a mitochondrial PP2A that dephosphorylates 
and inactivates the major anti-apoptotic 
protein Bcl-2 [116]. In vitro and in vivo studies 
pointed out to associations between Cer 
and Aβ. Endogenous pool of Cer strictly 
regulates Aβ biogenesis, in a way that elevated 
ceramide levels directly increase Aβ level 
[117]. Membrane Cer, as the major component 
of lipid rafts, facilitate Aβ production by 
increasing the half-life of β-secretase (BACE1) 
and affecting its molecular stability [117,118]. 
In turn, oligomeric soluble Aβ and fibrillar Aβ1-42 
activates neutral and acidic sphingomyelinases 
[119,120]. Hence, Aβ-dependent increase in 
ceramide levels leads to further increase in Aβ 
production (Figure 1). In addition, upregulated 
sphingomyelinase correlates with increased 
tau hyperphosphorylation in AD brains [112]. 
On the other hand, activation of SPT also 
might increase Cer levels and contribute to AD 
pathology. SPT consists of SPTLC1 and SPTLC2 
subunits, and expression of both has been 
confirmed in senile plaques [121]. 
Interaction of astroglia and neurons 
in sphingolipid metabolism and AD 
pathology
SPT upregulation in astrocytes is implicated 
in upregulation of sphingomyelinase activity 
in neurons. Soluble products released from 
palmitic acid (PA)-activated human astroglia 
activates neutral sphyngomyelinase and 
increases Cer levels and cell death in primary 
neuronal cultures [122]. In particular, exposure 
to PA, the most common saturated fatty 
acid, increases endogenous Cer production 
in astroglia, which in turn is involved in 
both increased amyloidogenesis and tau 
hyperphosphorylation in neurons exposed 
to conditioned media from PA-treated 
astrocytes [118,123]. As direct treatment of 
primary neurons with PA had no effect on 
the BACE1 activity and Aβ levels [124], such 
studies emphasized the essential role of 
abnormal astroglial Cer metabolism in causing 
pathophysiological changes characteristic of 
AD. PA-induced SPT activation and de novo 
synthesis of Cer in astrocytes is involved in 
the production of the cytokines TNF-α and IL-
1β. These soluble cytokines, after release into 
conditioned media activate sphingomyelinases 
in neurons, and through the catabolic 
pathway, increase Cer level and upregulate 
BACE1 and amyloidogenesis [123]. Increased 
extracellular Aβ could in turn act on both 
astroglia and neurons, and further enhance 
Cer levels, reinforcing a Cer-Aβ-Cer cascade 
[123]. Interestingly, the APP intracellular 
domain (AICD) decreases the expression of 
the SPTLC2, the catalytic subunit of the SPT 
heterodimer, decreasing the SPT activity [125]. 
Inhibition of SPT in an early-onset mouse 
model of AD by inhibitor L-cycloserine reduced 
cortical SPT protein levels, which in turn 
decreased Cer and induced downregulation 
of cortical Aβ1-42, and also decreased soluble 
hyperphosphorylated tau level without evident 
toxic effects [121]. Since L-cycloserine also acts 
as a partial agonist of N-methyl-D-aspartate 
receptors, cognitive enhancements have 
been observed following its administration 
in AD patients [126]. Likewise, treatment of 
neurons with conditioned media obtained 
from astroglia exposed to both free fatty acids 
and L-cycloserine was able to decrease levels 
of increased Aβ, hyperphosphorylated tau, 
and activated GSK-3β [118]. Other studies 
also linked Cer to tau phosphorylation. It was 
shown that Cer modulate PP2A activity [127], 
and increase tau phosphorylation by cdk5 at 
specific sites [128]. Beside direct impact on 
Aβ pathology, increase in Cer stimulates free 
radical generation, establishing a link between 
sphingolipid metabolism and oxidative stress 
that further exacerbates neuronal degeneration 
[98]. Hence, therapeutic strategies based on 
the reduction of Cer accumulation have the 
potential to prevent tau phosphorylation and 
further studies in  vivo are needed to clarify 
these approaches, particularly in combination 
with other targets. 
Conclusions
In spite of major research efforts, effective 
treatments for devastating neurodegenerative 
disorders, such as AD, are still lacking. As 
AD arise from the combination of different 
mechanisms (Figure 1), it is generally 
believed that prevention or reduction of AD 
pathology should rely on the inhibition of 
various steps involved in the early stages of 
disease progression. Several molecular targets 
represent rational therapeutic approaches for 
improvement of AD therapy. Among them are 
GSK-3β and enzymes involved in sphingolipid 
metabolism. GSK-3β has been identified as a 
major tau kinase and a signaling link between 
Aβ and tau pathology, and reduction of its 
activity certainly has valuable therapeutic 
potential. However, due to the large number 
of phosphorylation sites and the many 
protein kinases implicated in tau pathology, 
it is argued that valid strategies should be 
directed to overall reductions in cellular level 
of tau phosphorylation by targeting kinases 
with broad inhibitors. In addition, such an 
approach will probably have minor adverse 
effects on the physiological roles of targeted 
enzymes and fewer problems with tolerability 
and toxicity that are common in elderly [1]. 
Another prospective avenue in AD therapy is 
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